Fatal Relapse of Myelodysplastic Syndrome in a Patient with HIV/Hepatitis C Coinfection Treated with Simeprevir/Sofosbuvir

• Published in: Journal of the International Association of Providers of AIDS Care Vol. 16; no. 2; pp. 114 - 116
• Main Authors: Diejomaoh, Efemena Michael, Gathe, Joseph Clayton, Mayberry, Carl Craig, Clemmons, John Benjamin, Miguel, Bernie, Glombicki, Alan, Daquioag, Benjamin
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.03.2017; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: Antiviral Agents - therapeutic use; Antiviral drugs; Blood diseases; Cancer; Coinfection; Fatal Outcome; Hepatitis; Hepatitis C; Hepatitis C - complications; Hepatitis C - drug therapy; HIV; HIV Infections - complications; HIV Infections - drug therapy; Human immunodeficiency virus; Humans; Interferon; Kidney cancer; Male; Middle Aged; Myelodysplastic syndromes; Myelodysplastic Syndromes - complications; Patients; Prostate cancer; Recurrence; Relapse; Ribavirin - therapeutic use; Simeprevir - therapeutic use; Sofosbuvir - therapeutic use; Sustained Virologic Response; HIV/hepatitis C; ribavirin; SVR-12; simeprevir/sofosbuvir; myelodysplastic syndrome

Registrational studies and observational cohorts clearly suggest sustained virologic response (SVR) rates in HIV-/hepatitis C–coinfected patients are similar to monoinfected patients when utilizing interferon-free regimens, and this can be accomplished with agents that are well tolerated with minima...